Symbols / SPRC Stock $11.54 +21.99% SciSparc Ltd.

Healthcare • Biotechnology • Israel • NCM
SPRC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Oz Adler CPA
Exch · Country NCM · Israel
Market Cap 6.62M
Enterprise Value 3.30M
Income -12.18M
Sales 856.00K
FCF (ttm) 833.00K
Book/sh 142.32
Cash/sh 8.01
Employees 3
Insider 10d —
IPO Aug 30, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.12
Forward P/E —
PEG —
P/S 7.73
P/B 0.08
P/C —
EV/EBITDA -0.39
EV/Sales 3.85
Quick Ratio 2.13
Current Ratio 2.41
Debt/Eq 7.11
LT Debt/Eq —
EPS (ttm) 98.07
EPS next Y —
EPS Growth —
Revenue Growth -34.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -60.68%
ROE -178.39%
ROIC —
Gross Margin 73.71%
Oper. Margin -8.49%
Profit Margin 0.00%
Shs Outstand 573.24K
Shs Float 533.29K
Insider Own 0.00%
Instit Own 0.57%
Short Float 1.26%
Short Ratio 0.01
Short Interest 7.19K
52W High 80.10
vs 52W High -85.59%
52W Low 2.98
vs 52W Low 287.25%
Beta 2.43
Impl. Vol. —
Rel Volume 8.85
Avg Volume 993.64K
Volume 8.79M
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $9.46
Price $11.54
Change 21.99%
About

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$11.54
Latest analyst target
3. DCF / Fair value
$26.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.54
Low
—
High
—
Mean
—
News
RSS: Latest SPRC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-01 SHREM ITSCHAK Director — 462 $10.00 $4,620
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.86
-34.46%
1.31
-54.64%
2.88
+113.73%
1.35
Operating Revenue
0.86
-34.46%
1.31
-54.64%
2.88
+113.73%
1.35
Cost Of Revenue
0.23
-71.88%
0.80
+17.13%
0.68
+112.11%
0.32
Reconciled Cost Of Revenue
0.18
-72.95%
0.68
+8.40%
0.63
+95.96%
0.32
Gross Profit
0.63
+24.70%
0.51
-76.96%
2.20
+114.24%
1.02
Operating Expense
9.38
+21.06%
7.75
-2.77%
7.97
-14.42%
9.31
Research And Development
2.19
+20.44%
1.81
+5.10%
1.73
-41.73%
2.96
Selling General And Administration
5.44
-0.02%
5.44
-3.67%
5.65
-9.92%
6.27
Selling And Marketing Expense
0.72
-37.51%
1.15
-42.49%
2.00
+84.66%
1.08
General And Administrative Expense
4.72
+10.02%
4.29
+17.60%
3.65
-29.66%
5.19
Salaries And Wages
1.56
+68.57%
0.93
+91.72%
0.48
-54.86%
1.07
Other Gand A
3.16
-6.09%
3.36
+6.29%
3.17
-23.10%
4.12
Other Operating Expenses
1.56
+1120.31%
0.13
+16.36%
0.11
+37.50%
0.08
Total Expenses
9.61
+12.37%
8.55
-1.20%
8.65
-10.19%
9.63
Operating Income
-8.75
-20.81%
-7.24
-25.45%
-5.77
+30.34%
-8.29
Total Operating Income As Reported
-8.37
-14.46%
-7.32
-7.35%
-6.82
+17.76%
-8.29
EBITDA
-12.32
-76.64%
-6.97
-31.24%
-5.31
-125.65%
-2.35
Normalized EBITDA
-7.20
-6.41%
-6.77
-24.30%
-5.45
+42.15%
-9.41
Reconciled Depreciation
0.23
-51.45%
0.48
-10.41%
0.54
+187.70%
0.19
EBIT
-12.55
-68.36%
-7.46
-27.41%
-5.85
-130.21%
-2.54
Total Unusual Items
-5.12
-2383.98%
-0.21
-257.25%
0.13
-98.14%
7.06
Total Unusual Items Excluding Goodwill
-5.12
-2383.98%
-0.21
-257.25%
0.13
-98.14%
7.06
Special Income Charges
-3.39
-4485.14%
-0.07
+92.90%
-1.04
0.00
Other Special Charges
5.51
—
—
—
Impairment Of Capital Assets
0.12
-91.44%
1.34
+28.98%
1.04
0.00
Restructuring And Mergern Acquisition
—
—
—
0.91
Write Off
—
—
—
0.00
Net Income
-12.18
-93.81%
-6.28
-22.69%
-5.12
-97.61%
-2.59
Pretax Income
-12.56
-67.83%
-7.49
-27.73%
-5.86
-127.35%
-2.58
Net Non Operating Interest Income Expense
1.78
+354.22%
0.39
+4444.44%
-0.01
+99.27%
-1.24
Interest Expense Non Operating
0.01
-63.33%
0.03
+233.33%
0.01
-75.00%
0.04
Net Interest Income
1.78
+354.22%
0.39
+4444.44%
-0.01
+99.27%
-1.24
Interest Expense
0.01
-63.33%
0.03
+233.33%
0.01
-75.00%
0.04
Interest Income Non Operating
0.21
-50.83%
0.42
0.00
0.00
Interest Income
0.21
-50.83%
0.42
0.00
0.00
Other Income Expense
-5.59
-780.47%
-0.64
-703.80%
-0.08
-101.14%
6.95
Other Non Operating Income Expenses
0.03
—
—
—
Gain On Sale Of Security
-1.72
-1206.06%
-0.13
-111.25%
1.17
-83.38%
7.06
Gain On Sale Of Business
2.23
0.00
0.00
—
Tax Provision
0.00
+100.00%
-0.01
-163.64%
0.02
+57.14%
0.01
Tax Rate For Calcs
0.00
-100.00%
0.00
-99.19%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.00
-101.28%
0.03
-98.14%
1.62
Net Income Including Noncontrolling Interests
-12.56
-68.15%
-7.47
-27.01%
-5.88
-126.97%
-2.59
Net Income From Continuing Operation Net Minority Interest
-12.18
-93.81%
-6.28
-22.69%
-5.12
-97.61%
-2.59
Net Income From Continuing And Discontinued Operation
-12.18
-93.81%
-6.28
-22.69%
-5.12
-97.61%
-2.59
Net Income Continuous Operations
-12.56
-68.15%
-7.47
-27.01%
-5.88
-126.97%
-2.59
Net Income Discontinuous Operations
—
—
—
—
Minority Interests
0.39
-67.59%
1.19
+56.11%
0.76
0.00
Normalized Income
-7.06
-16.18%
-6.08
-16.38%
-5.22
+34.93%
-8.03
Net Income Common Stockholders
-12.18
-93.81%
-6.28
-22.69%
-5.12
-97.61%
-2.59
Diluted EPS
—
203.89
-91.41%
2,374.55
+226.70%
-1,874.19
Basic EPS
—
203.89
-91.41%
2,374.55
+226.70%
-1,874.19
Basic Average Shares
—
0.03
+1328.84%
0.00
+55.97%
0.00
Diluted Average Shares
—
0.03
+1328.84%
0.00
+55.97%
0.00
Diluted NI Availto Com Stockholders
-12.18
-93.81%
-6.28
-22.69%
-5.12
-97.61%
-2.59
Average Dilution Earnings
0.00
0.00
0.00
0.00
Amortization
0.19
-46.99%
0.37
-24.69%
0.49
—
Amortization Of Intangibles Income Statement
0.19
-46.99%
0.37
-24.69%
0.49
—
Depreciation Amortization Depletion Income Statement
0.19
-46.99%
0.37
-24.69%
0.49
—
Depreciation And Amortization In Income Statement
0.19
-46.99%
0.37
-24.69%
0.49
—
Earnings From Equity Interest
-0.50
-16.55%
-0.43
-104.29%
-0.21
-92.66%
-0.11
Gain On Sale Of PPE
0.00
-100.00%
1.27
0.00
0.00
Total Other Finance Cost
-1.58
—
-2.21
-283.14%
1.20
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
7.62
-26.34%
10.35
-7.47%
11.18
+5.44%
10.61
Current Assets
5.44
-27.55%
7.50
+16.42%
6.45
+42.90%
4.51
Cash Cash Equivalents And Short Term Investments
4.59
+123.19%
2.06
-59.48%
5.08
+42.03%
3.57
Cash And Cash Equivalents
4.59
+198.12%
1.54
-25.82%
2.08
-41.91%
3.57
Cash Financial
4.59
+198.12%
1.54
-25.82%
2.08
-41.91%
3.57
Other Short Term Investments
0.00
-100.00%
0.52
-82.77%
3.00
0.00
Receivables
0.66
-86.66%
4.96
+1629.27%
0.29
+70.83%
0.17
Accounts Receivable
0.01
+0.00%
0.01
-54.55%
0.02
-71.43%
0.08
Other Receivables
0.19
-73.95%
0.71
+169.43%
0.27
+191.21%
0.09
Loans Receivable
0.45
-89.32%
4.22
0.00
—
Inventory
0.07
-33.63%
0.11
-84.77%
0.74
+11.08%
0.67
Finished Goods
0.07
-33.63%
0.11
-84.77%
0.74
+11.08%
0.67
Prepaid Assets
0.09
-74.86%
0.35
+27.27%
0.28
+587.50%
0.04
Restricted Cash
0.02
+0.00%
0.02
-69.23%
0.07
+8.33%
0.06
Total Non Current Assets
2.19
-23.14%
2.84
-39.96%
4.74
-22.28%
6.09
Net PPE
0.02
-67.80%
0.06
-45.37%
0.11
+89.47%
0.06
Gross PPE
0.10
+1.01%
0.10
-56.00%
0.23
+84.43%
0.12
Accumulated Depreciation
-0.08
-102.50%
-0.04
+65.81%
-0.12
-80.00%
-0.07
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.07
+0.00%
0.07
-58.56%
0.18
+132.05%
0.08
Machinery Furniture Equipment
0.03
+4.17%
0.02
-45.45%
0.04
+0.00%
0.04
Leases
—
—
0.18
+132.05%
0.08
Goodwill And Other Intangible Assets
1.17
-20.89%
1.48
-53.62%
3.19
-32.39%
4.72
Investments And Advances
1.00
-23.66%
1.31
-9.31%
1.44
+9.01%
1.32
Long Term Equity Investment
0.00
-100.00%
0.95
+21.90%
0.78
+32.15%
0.59
Total Liabilities Net Minority Interest
2.48
+75.78%
1.41
-11.72%
1.59
-61.62%
4.16
Current Liabilities
2.25
+61.04%
1.40
-10.95%
1.57
-62.20%
4.16
Payables And Accrued Expenses
1.37
+53.98%
0.89
+0.91%
0.88
-32.85%
1.31
Payables
1.29
+57.72%
0.82
-2.28%
0.83
+167.63%
0.31
Accounts Payable
0.78
-4.04%
0.82
+1.75%
0.80
+169.13%
0.30
Other Payable
—
—
0.03
+135.71%
0.01
Current Accrued Expenses
0.09
+13.33%
0.07
+56.25%
0.05
-95.21%
1.00
Pensionand Other Post Retirement Benefit Plans Current
0.17
+34.62%
0.13
+25.00%
0.10
+35.06%
0.08
Current Debt And Capital Lease Obligation
0.37
+889.19%
0.04
-28.85%
0.05
+92.59%
0.03
Current Debt
0.36
—
—
—
Other Current Borrowings
0.36
—
—
—
Current Capital Lease Obligation
0.01
-72.97%
0.04
-28.85%
0.05
+92.59%
0.03
Other Current Liabilities
0.34
-0.29%
0.34
-35.90%
0.53
-80.56%
2.74
Total Non Current Liabilities Net Minority Interest
0.22
+2366.67%
0.01
-62.50%
0.02
0.00
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.01
-62.50%
0.02
0.00
Long Term Capital Lease Obligation
0.00
-100.00%
0.01
-62.50%
0.02
0.00
Tradeand Other Payables Non Current
0.00
0.00
—
—
Stockholders Equity
4.24
-48.01%
8.15
+7.09%
7.61
+18.06%
6.45
Common Stock Equity
4.24
-48.01%
8.15
+7.09%
7.61
+18.06%
6.45
Capital Stock
76.48
+7.89%
70.89
+9.86%
64.53
+10.13%
58.59
Common Stock
76.48
+7.89%
70.89
+9.86%
64.53
+10.13%
58.59
Share Issued
0.37
+537.86%
0.06
+1432.28%
0.00
+170.35%
0.00
Ordinary Shares Number
0.37
+537.86%
0.06
+1432.28%
0.00
+170.35%
0.00
Retained Earnings
-87.15
-16.24%
-74.97
-9.15%
-68.69
-8.06%
-63.57
Gains Losses Not Affecting Retained Earnings
1.91
+283.70%
0.50
+0.00%
0.50
+0.00%
0.50
Minority Interest
0.91
+15.67%
0.79
-60.21%
1.97
0.00
Total Equity Gross Minority Interest
5.15
-42.42%
8.94
-6.76%
9.59
+48.66%
6.45
Total Capitalization
4.24
-48.01%
8.15
+7.09%
7.61
+18.06%
6.45
Working Capital
3.18
-47.85%
6.10
+25.24%
4.87
+1276.84%
0.35
Invested Capital
4.59
-43.65%
8.15
+7.09%
7.61
+18.06%
6.45
Total Debt
0.37
+695.65%
0.05
-39.47%
0.08
+181.48%
0.03
Capital Lease Obligations
0.01
-78.26%
0.05
-39.47%
0.08
+181.48%
0.03
Net Tangible Assets
3.07
-54.02%
6.67
+50.85%
4.42
+155.48%
1.73
Tangible Book Value
3.07
-54.02%
6.67
+50.85%
4.42
+155.48%
1.73
Duefrom Related Parties Current
0.01
+0.00%
0.01
0.00
—
Dueto Related Parties Current
0.50
0.00
—
—
Dueto Related Parties Non Current
0.22
0.00
—
—
Foreign Currency Translation Adjustments
1.91
+283.70%
0.50
+0.00%
0.50
+0.00%
0.50
Investmentin Financial Assets
1.00
+181.64%
0.35
-46.28%
0.66
-9.73%
0.73
Investmentsin Associatesat Cost
0.00
-100.00%
0.95
+21.90%
0.78
+32.15%
0.59
Other Equity Interest
13.01
+10.72%
11.75
+4.11%
11.28
+3.23%
10.93
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-4.14
+18.95%
-5.10
+13.30%
-5.89
+25.64%
-7.92
Cash Flow From Continuing Operating Activities
-4.14
+18.95%
-5.10
+13.30%
-5.89
+25.64%
-7.92
Net Income From Continuing Operations
-12.56
-68.15%
-7.47
-27.01%
-5.88
-126.97%
-2.59
Depreciation Amortization Depletion
0.23
-51.45%
0.48
-10.41%
0.54
+187.70%
0.19
Depreciation And Amortization
0.23
-51.45%
0.48
-10.41%
0.54
+187.70%
0.19
Other Non Cash Items
-2.00
-122.74%
-0.90
+59.32%
-2.21
+66.51%
-6.58
Stock Based Compensation
1.19
+108.79%
0.57
+190.31%
0.20
-78.15%
0.90
Asset Impairment Charge
6.09
+352.98%
1.34
+28.98%
1.04
0.00
Operating Gains Losses
1.47
+100.27%
0.73
-41.65%
1.26
+43.12%
0.88
Gain Loss On Investment Securities
1.79
+487.21%
0.30
-70.90%
1.05
+36.10%
0.77
Net Foreign Currency Exchange Gain Loss
1.41
0.00
0.00
—
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
1.45
+962.50%
0.14
+116.33%
-0.83
-18.49%
-0.70
Change In Receivables
0.79
+251.05%
-0.52
-47.74%
-0.35
-378.38%
-0.07
Changes In Account Receivables
0.00
-100.00%
0.01
-78.18%
0.06
+171.43%
-0.08
Change In Inventory
0.04
-93.96%
0.63
+950.00%
-0.07
+88.92%
-0.67
Change In Payables And Accrued Expense
-0.11
-342.22%
0.04
+111.11%
-0.41
-1138.46%
0.04
Change In Payable
-0.11
-342.22%
0.04
+111.11%
-0.41
-1138.46%
0.04
Change In Account Payable
-0.16
-756.00%
0.03
+106.30%
-0.40
0.00
Change In Other Working Capital
0.73
+4940.00%
-0.01
—
—
Investing Cash Flow
-1.40
+13.85%
-1.62
+60.31%
-4.09
+42.21%
-7.08
Cash Flow From Continuing Investing Activities
-1.40
+13.85%
-1.62
+60.31%
-4.09
+42.21%
-7.08
Net PPE Purchase And Sale
0.00
-100.00%
0.01
0.00
+100.00%
-0.01
Purchase Of PPE
—
—
0.00
+100.00%
-0.01
Sale Of PPE
—
—
—
—
Capital Expenditure
—
—
—
-4.87
Net Investment Purchase And Sale
0.00
-100.00%
3.00
+181.32%
-3.69
-145.93%
-1.50
Purchase Of Investment
0.00
0.00
+100.00%
-3.69
-145.93%
-1.50
Sale Of Investment
0.00
-100.00%
3.00
—
—
Net Business Purchase And Sale
0.60
+200.00%
-0.60
-50.00%
-0.40
+42.86%
-0.70
Purchase Of Business
-0.10
+83.33%
-0.60
-50.00%
-0.40
+42.86%
-0.70
Net Intangibles Purchase And Sale
—
0.00
0.00
+100.00%
-4.86
Purchase Of Intangibles
—
0.00
0.00
+100.00%
-4.86
Net Other Investing Changes
-2.00
+50.41%
-4.03
-80560.00%
-0.01
+66.67%
-0.01
Financing Cash Flow
8.59
+38.67%
6.19
-27.00%
8.48
-27.50%
11.70
Cash Flow From Continuing Financing Activities
8.59
+38.67%
6.19
-27.00%
8.48
-27.50%
11.70
Net Issuance Payments Of Debt
4.50
+8433.33%
-0.05
-14.89%
-0.05
+32.86%
-0.07
Issuance Of Debt
4.54
0.00
0.00
0.00
Repayment Of Debt
-0.04
+29.63%
-0.05
-14.89%
-0.05
+32.86%
-0.07
Long Term Debt Issuance
4.35
0.00
0.00
—
Long Term Debt Payments
-0.04
+29.63%
-0.05
-14.89%
-0.05
+32.86%
-0.07
Net Long Term Debt Issuance
4.31
+8077.78%
-0.05
-14.89%
-0.05
+32.86%
-0.07
Short Term Debt Issuance
0.19
0.00
0.00
0.00
Short Term Debt Payments
—
—
0.00
0.00
Net Short Term Debt Issuance
0.19
0.00
0.00
0.00
Net Common Stock Issuance
2.97
-52.49%
6.25
+12.66%
5.55
-38.35%
9.01
Cash Dividends Paid
0.00
0.00
0.00
0.00
Proceeds From Stock Option Exercised
1.12
0.00
0.00
-100.00%
2.77
Net Other Financing Charges
—
—
2.98
+99400.00%
0.00
Changes In Cash
3.05
+669.22%
-0.54
+64.22%
-1.50
+54.62%
-3.30
Effect Of Exchange Rate Changes
—
—
—
—
Beginning Cash Position
1.54
-25.82%
2.08
-41.91%
3.57
-48.01%
6.88
End Cash Position
4.59
+198.12%
1.54
-25.82%
2.08
-41.91%
3.57
Free Cash Flow
-4.14
+18.95%
-5.10
+13.30%
-5.89
+53.96%
-12.79
Common Stock Issuance
2.97
-52.49%
6.25
+12.66%
5.55
-38.35%
9.01
Earnings Losses From Equity Investments
-1.73
-503.50%
0.43
+104.29%
0.21
+92.66%
0.11
Interest Paid CFF
-0.01
+37.50%
-0.01
-14.29%
-0.01
+12.50%
-0.01
Issuance Of Capital Stock
2.97
-52.49%
6.25
+12.66%
5.55
-38.35%
9.01
Sale Of Business
0.70
0.00
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category